{"id":"W2168911501","doi":"10.1016/s0140-6736(05)67763-x","title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","year":2005,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1069,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Western University","funders":"Amgen","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Etanercept; Psoriasis; Internal medicine; Depression (economics); Physical therapy; Beck Depression Inventory; Adverse effect; Clinical endpoint; Randomized controlled trial; Clinical trial; Psychiatry; Rheumatoid arthritis; Anxiety; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07492228636010856,"score_gpt":0.3600600821513356,"score_spread":0.285137795791227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}